An important representative of this virus family is T-VEC (Imlygic®), the only virus construct approved in the western hemisphere for virotherapy to date, which is characterized by the additional integration of the gene encoding human granulocyte-macrophage colony-stimulating factor (hGM-CSF), intended to trigger an enhancement of the virus-mediated anti-tumor immune response. This evidence concerns the gene CSF2 and neoplasm.